8-K filing — Veradermics, Inc (MANE)
Filed: 2026-11-09 AccNo: 0001827635-26-000038 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results
Veradermics reports positive Phase 2/3 trial data for its oral hair loss pill, paving the way for potential FDA approval. MANE shares rise.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Veradermics Announces Topline Results from Phase 3 Clinical Trial of VDPHL01
Veradermics, Incorporated reported topline results from its registration-directed Phase 3 clinical trial (Study '302') evaluating VDPHL01 for the treatment of pattern hair loss.
Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss
Veradermics Announces Investor Call to Review Phase 3 Clinical Trial Results for VDPHL01
Veradermics, Incorporated announced it will host an investor call and live webcast on November 9, 2026, to discuss topline results from its Phase 3 clinical trial of VDPHL01.
Connecticut Innovations Reports Record Venture Proceeds Driven by Veradermics IPO
Connecticut Innovations announced record-breaking quarterly venture proceeds of $51.4 million, largely attributed to the initial public offering of its portfolio company, Veradermics, Incorporated.
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204